Market Overview

KEDPLASMA USA Expanding with Two More Plasma Collection Centers; Ongoing Growth Continues to Benefit Rare Disease Patients

    , a leading human blood plasma collection and procurement
    specialist, has added two additional plasma collection centers, one in
    College Park, Georgia, and another in Longview, Texas.
  • Both locations are considered strategically important as KEDPLASMA USA
    advances its long-term growth plan in the U.S.
  • By 2022, the number of KEDPLASMA USA collection centers will have
    nearly doubled, to a total of more than 30 across the U.S. The
    Atlanta, Georgia, and Longview, Texas centers are the Company's 16th
    and 17th centers, respectively.
  • The U.S. plasma market is projected to be nearly $37B by 2023.
  • Plasma is a key component in a range of therapies used in treating
    certain rare diseases; KEDPLASMA USA's growth benefits patients who
    rely on those therapies.

, one of the world's leading collectors of high-quality human
blood plasma, has added two plasma collection centers to its growing
network – one in Atlanta, Georgia, and another in Longview, Texas. Both
locations are considered to be strategically important to the Company as
the demand for plasma continues to accelerate. Indeed, the global plasma
protein therapeutics market is estimated to be at approximately USD $24
billion currently, and is poised to reach nearly $37 billion by 2023,
with a consolidated annual growth rate of approximately 9%, according to
industry analysts.

This press release features multimedia. View the full release here:

KEDPLASMA USA Plasma Center in College Park, Atlanta, GA (Photo: Business Wire)

KEDPLASMA USA Plasma Center in College Park, Atlanta, GA (Photo: Business Wire)

The centers are part of a KEDPLASMA USA five-year plan to bring the
number of plasma collection centers that it owns and operates to a total
of over 30 by the year 2022. Plasma is a key component in a range of
therapies used in treating diseases or conditions such as hemophilia,
primary immune deficiency, rabies, prevention of Rh
, and others. Therefore, as KEDPLASMA USA expands its
operations, more patients across the U.S. may have access to the
important therapies that, ultimately, are derived from the collected
plasma. With the two newest additions to its suite, KEDPLASMA USA now
owns and operates 17
plasma collection centers

"More and more people are being diagnosed with serious, sometimes
life-threatening diseases, a number of which are treated with products
derived from safe, high quality plasma," said Helen Nasser, Managing
Director of KEDPLASMA USA. "KEDPLASMA USA is tracking this trend
closely, expanding our collection center network in line with a
long-range plan designed to help ensure more patients have ongoing
access to those products, even as the demand for them accelerates. We
are excited by the growth we are achieving and by what it means for
patients who benefit from plasma-derived medicines, now and well into
the future."

KEDPLASMA LLC collects plasma for Kedrion
Biopharma Inc.
, which is headquartered in Fort Lee, New Jersey and
which is the U.S. subsidiary of Kedrion S.p.A. (Kedrion Biopharma) of
Lucca, Italy. Kedrion Biopharma commercializes safe, effective,
plasma-derived therapies that treat a range of rare and serious health
conditions, including hemophilia,
and neurological conditions
, and certain acute, life-threatening
conditions requiring treatment in the critical care setting.

KEDPLASMA is also one of the largest suppliers of high titer rabies
plasma in the world. All centers owned and operated by KEDPLASMA USA are
regulated by the U.S. Food and Drug Administration and are monitored by
the relevant European healthcare regulation authorities.

About KEDPLASMA and Kedrion Biopharma

KEDPLASMA LLC was established in 2004 and is a subsidiary of Kedrion
Biopharma Inc., the U.S. subsidiary of Kedrion S.p.A.. Kedrion Biopharma
Inc. and KEDPLASMA LLC. are both headquartered in the United States.
KEDPLASMA collects high quality human blood plasma, the vital raw
material that allows Kedrion Biopharma to produce and distribute
plasma-derived therapeutic products for use in treating and/or
preventing serious diseases and conditions such as hemophilia, primary
immune system deficiencies and Rh sensitization which can lead to
hemolytic disease of the fetus and newborn.

Headquartered in Tuscany, Italy, Kedrion Biopharma has a market presence
in approximately 100 countries. It ranks fifth in terms of annual
revenues in the global plasma derivatives market. Its largest and
fastest growing market is the United States, with U.S. headquarters in
Fort Lee, NJ. Italy is its next most important market, followed by
Turkey, Mexico and Russia. In 2017, Kedrion Biopharma ended with 602.5
million euros (more than $706 MM USD) in gross revenues. Nearly $288
million of that sum was generated in the U.S. The company employs over
2,450 people worldwide.

Kedrion Biopharma acts as a vital bridge connecting donors and patients.
We operate on a global scale with the aim of expanding patients' access
to available treatments. Kedrion Biopharma places a high value on the
welfare of those who benefit from its products and on the people and
communities where it operates.

Following a vertically-integrated business model, Kedrion Biopharma
manages the entire plasma cycle from supply and therapy production to
distribution. In Italy, Kedrion Biopharma is a partner of the National
Health Service and collaborates in pursuing self-sufficiency in the
development and supply of plasma-derived medicinal products. The
Company's goal is to foster self-sufficiency in plasma-derived therapies
worldwide and to bring healthier lives to people everywhere who suffer
from rare disorders.

Kedrion Biopharma has six production plants: Three in Italy (a new plant
in Castelvecchio Pascoli, now nearing completion, and one in Bolognana,
both in the province of Lucca, and one in Sant'Antimo, Naples); one in
Hungary (Gödöllő, Budapest); and one in the United States (Melville,
NY). A facility in Siena, Tuscany, specializes in research and
development of orphan drugs.

KEDPLASMA operates collection centers in the United States. Its sister
companies in Europe operate centers in Germany and Hungary. All centers
are granted approval and licensure by European healthcare authorities
and/or the U.S. Food and Drug Administration and are managed in strict
compliance with all regulations. KEDPLASMA is also one of the world's
leading suppliers of high-titer rabies plasma. The center in Buffalo,
New York, specializes in collecting hyper-immune Anti-D human plasma for
the manufacture of an Anti-D immunoglobulin pharmaceutical product.
State-of-the-art production facilities producing a wide range of
products and an unwavering commitment to research and development are
the key factors in Kedrion Biopharma's success.

View Comments and Join the Discussion!